Cytogenetic Alterations in Multiple Myeloma: Prognostic Significance and the Choice of Frontline Therapy.
Multiple myeloma tumor cells demonstrate multiple and often complex genetic lesions as evaluated by standard cytogenetic/FISH studies. Over the past decade, specific abnormalities have been associated with standard or high-risk clinical behavior and they have become strong prognostic indicators. Further, as evidenced by recent randomized clinical trials, the choice of front-line therapy (transplant vs. no transplant, inclusion of novel drugs such as bortezomib, thalidomide, and lenalidomide) may be able to overcome the adverse effect of high-risk genetic lesions.
a Laboratorio de Genética de Neoplasias Linfoides, Instituto de Medicina Experimental, CONICET-Academia Nacional de Medicina , Buenos Aires , Argentina.
Flavia
F
Stella
a Laboratorio de Genética de Neoplasias Linfoides, Instituto de Medicina Experimental, CONICET-Academia Nacional de Medicina , Buenos Aires , Argentina.
Estela
E
Pedrazzini
b Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina , Buenos Aires , Argentina.
Mara
M
Agazzoni
b Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina , Buenos Aires , Argentina.
Oscar
O
Ballester
a Laboratorio de Genética de Neoplasias Linfoides, Instituto de Medicina Experimental, CONICET-Academia Nacional de Medicina , Buenos Aires , Argentina.
Irma
I
Slavutsky
D003582:Cytogenetics / Q000379:methods*; D005260:Female; D006801:Humans; D008297:Male; D009101:Multiple Myeloma / Q000188:drug therapy / Q000235:genetics*; D011379:Prognosis; D012307:Risk Factors
Bortezomib; Cytogenetics; FISH; MGUS; Multiple mieloma; Prognostic factors; Risk groups; Thalidomide; Therapy